GNLX
Genelux Corporation Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$130.93M
P/E Ratio
—
EPS
$-0.85
Beta
0.50
52W High
$8.54
52W Low
$2.29
50-Day MA
$2.69
200-Day MA
$3.77
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The company is headquartered in Westlake Village, California.
Fundamentals
| Revenue (TTM) | 8,000 |
| Gross Profit (TTM) | 8,000 |
| EBITDA | $-34.38M |
| Operating Margin | -432112.00% |
| Return on Equity | -127.30% |
| Return on Assets | -60.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.31 |
| Price-to-Book | 5.71 |
| Price-to-Sales (TTM) | 16366.75 |
| EV/Revenue | 13402.5 |
| EV/EBITDA | -327.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.30% |
| Shares Outstanding | $44.84M |
| Float | $36.53M |
| % Insiders | 10.74% |
| % Institutions | 30.68% |
Historical Volatility
HV 10-Day
69.16%
HV 20-Day
67.78%
HV 30-Day
63.82%
HV 60-Day
67.05%
HV Rank
15.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($17.50 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026